Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Krystal Biotech ( (KRYS) ) just unveiled an update.
On January 11, 2026, Krystal Biotech reported selected preliminary, unaudited 2025 results and a strategic business update ahead of its presentation at the 44th Annual J.P. Morgan Healthcare Conference, highlighting that VYJUVEK generated an estimated $106–107 million in net product revenue in the fourth quarter of 2025 and $388–389 million for the full year, with cash, cash equivalents and investments of about $955 million as of December 31, 2025. Management outlined an aggressive rare disease growth strategy built on its HSV-1 platform, including plans to accelerate development of key pipeline candidates KB803, KB801, KB407 and KB111, expand VYJUVEK’s global footprint, and pursue at least four marketed rare disease medicines treating more than 10,000 patients by 2030, while maintaining profitability and investing in larger indications such as alpha-1 antitrypsin deficiency and non-small cell lung cancer, signaling confidence in sustained growth and a multibillion-dollar opportunity set for investors and stakeholders.
The most recent analyst rating on (KRYS) stock is a Buy with a $310.00 price target. To see the full list of analyst forecasts on Krystal Biotech stock, see the KRYS Stock Forecast page.
Spark’s Take on KRYS Stock
According to Spark, TipRanks’ AI Analyst, KRYS is a Outperform.
The score is driven primarily by strong financial quality (high margins, minimal leverage) and favorable technical trend (price above major moving averages with positive MACD). Earnings updates and recent corporate milestones add support via strong VYJUVEK execution and encouraging pipeline progress, while a premium valuation (P/E ~36.95) and recent free-cash-flow growth decline temper the upside.
To see Spark’s full report on KRYS stock, click here.
More about Krystal Biotech
Krystal Biotech, Inc. (NASDAQ: KRYS) is a fully integrated, commercial-stage global biotechnology company focused on discovering, developing and commercializing genetic medicines for diseases with high unmet medical need. Its first commercial product, VYJUVEK, is the first-ever redosable gene therapy and the first genetic medicine approved in the United States, Europe and Japan for dystrophic epidermolysis bullosa, and the company is advancing a broad preclinical and clinical pipeline leveraging its HSV-1 gene-delivery platform for skin, lung and eye indications.
Average Trading Volume: 297,235
Technical Sentiment Signal: Buy
Current Market Cap: $7.22B
See more data about KRYS stock on TipRanks’ Stock Analysis page.